{"id":881940,"date":"2025-09-04T09:16:52","date_gmt":"2025-09-04T13:16:52","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-to-participate-in-september-investor-conferences\/"},"modified":"2025-09-04T09:16:52","modified_gmt":"2025-09-04T13:16:52","slug":"cidara-therapeutics-to-participate-in-september-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-to-participate-in-september-investor-conferences\/","title":{"rendered":"Cidara Therapeutics to Participate in September Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SAN DIEGO, Sept.  04, 2025  (GLOBE NEWSWIRE) &#8212; Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak<sup>\u00ae<\/sup> platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that company management will participate in the below September investor conferences.<\/p>\n<p align=\"justify\">Details are as follows:<\/p>\n<p align=\"justify\">\n        <strong>Event<\/strong>: H.C. Wainwright 27<sup>th<\/sup> Annual Global Investment Conference<br \/><strong>Date<\/strong>: September 8, 2025<br \/><strong>Time: <\/strong>4:00 PM ET<br \/><strong>Format: <\/strong>Corporate Presentation<\/p>\n<p align=\"justify\">\n        <strong>Event<\/strong>: Morgan Stanley 23<sup>rd<\/sup> Annual Global Healthcare Conference<br \/><strong>Date<\/strong>: September 9, 2025<br \/><strong>Time: <\/strong>7:00 AM ET<br \/><strong>Format: <\/strong>Fireside Chat<\/p>\n<p align=\"justify\">Cidara will also participate in one-on-one investor meetings during the conferences.<\/p>\n<p>\n        <strong>About Cidara Therapeutics<\/strong><br \/>\n        <br \/>Cidara Therapeutics is using its proprietary Cloudbreak<sup>\u00ae<\/sup>\u00a0platform to develop novel drug-Fc conjugates (DFCs) comprising targeted small molecules or peptides coupled to a proprietary human antibody fragment. Cidara\u2019s lead DFC candidate, CD388, is a long-acting antiviral designed to achieve universal prevention of seasonal and pandemic influenza with a single dose by directly inhibiting viral proliferation. In June 2023, CD388 was granted Fast Track Designation by the FDA. Cidara announced positive top-line results from its Phase 2b NAVIGATE trial in June 2025. Additional DFCs have been developed for oncology and in July 2024 Cidara received investigational new drug application clearance for CBO421 which is intended to target CD73 in solid tumors. Cidara is headquartered in San Diego, California. For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RUlrRoBRSSm3pHVQ1SW4TcyO6hla3D8qeq9ScNQ52Yav-VkoxOfNqKoFEbxJXGAj4p5c-BGRfGmOu02tm8t5qFkNVa1WQp5WPan5Wg5GO0f24RXZVbXOY2N6UfjEVKkE2gSf2dk7gy2QzvenphVFQ2LqXOFPTdff_r6MCmuQnZHKmi3xPE-e-g1aX3cvT37QfCrWB722nY3dlNK4VbXzPknlFYZk4MahfvxTMae0E6KUkcjQRd4Qf7TYy6yfBeF0V-WYNkh7H9lQIg-4gUYJ_8PG0ern0z8ajj49ce0_opp_rAHfEd4quoJ6xKT3N7Q8yqDCazmVeXKLjx3XQdxBzavjMKpeqmgacrapn4glM9K6VPoPdoscITKL0c7YJM4mWg_9WZA_vDjFE-RY4tMvhuTWg7Ny4EvNdmakHk_moIkhQqpJMhf5GO2Zpqv2F6XBvlLB41rqJdL742A77myTCoyjnWJR4_u-xgFT9FCCoYVOx9j5Cm9wsdUa2IJ4hiwvS6rXa3t512tujkJidYLbQZd5E6ZFgK5OGSoEEjFZD1AxMR34GEgKX_OoFO2Wnf00zo7dwrK8z5qurXhY-64Ak3LLNRwE_JDgPbqZpaGm1TZxx4fwCjP7xG3tmsd8jjCyXBfYnEKgQasboaorj2Yev62M-gLZxwvHUFtEWzc7l3h4j8DU2On9EGb-_VkHh7c62bHtcNHmaxMNwejNyGXmUSeUDSXuX5qGcfiLKNsliZ89u6xHu8fAwBx3c8zSVce0bHd1UyJHbgd_KCh0SsP0noV2OMeD9eiA-7qBL1pDteKqUwCRzulJZpviEh8DP4iGfePyyp5jGxGuC1dnN-MyNcUmdG6OWC_K7CPb1Q6lQmuzRINgNhIA23twyN1fUE6gTj6FuUezPgV4I19zU5ChSuG4SSbRkdotzQl3kOCNm9Xh8F7OUrKQSnvS-4PjYbumgUuJtb0cnVr2T8aYS8XszAmrKB7LEU-RvThfugvNwH2XdHTnbLtPuPAJFoX4c1l8a1RVer3IOTZQZ3Kimt92Qp_7mG-uqJK09gTbiM-8K9u4zqmyPRhPrRDEkbbzf5KM_8hPMOuLNn-j5zX3PwTB22cOu3Y6n2bFimZkkPuJzu6P-qdDlDeGdjzI3oiQ2HYe96ARcoqFHDu47mqMovtk3ZIHIHvoVeg7j4Kigtn1c-Nk1dnqr86ayfNI4XYQo3ImohVWKCHpV2YmDDdCOmHlQAANL8SXs135WGGNyCJxtz-Tr0hcccut-M4xJb4h5o5T08Xi4UQIyjItAi6N7gnscxA7O6buzsHYkL72VerL4ic=\" rel=\"nofollow\" target=\"_blank\">www.cidara.com<\/a>.<\/p>\n<p>\n        <strong>INVESTOR CONTACT:<\/strong><br \/>\n        <br \/>Brian Ritchie<br \/>LifeSci Advisors<br \/>(212) 915-2578<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ogNU-pVsVZfjQCGl7VNMKvS_q18RsujIkf6J48XZf-G7fml9ckDWI9TNA1YXq-4EAQBX-lLWuzWujOEcbucBbm3ZgF36mh_8ikzFVgedLMoumt2H2aBQ9m_cLtn3zyRt\" rel=\"nofollow\" target=\"_blank\">britchie@lifesciadvisors.com<\/a><\/p>\n<p>\n        <strong>MEDIA CONTACT:<\/strong><br \/>\n        <br \/>Michael Fitzhugh<br \/>LifeSci Communications<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=F5Lb9W6PZcskiC-D5VDGjFm_busOB4yNkbsCwMDV2P3jXyVJGeQdPX87sVVUJjRlaTf1r9WD0CTVyXmKGHZCnskAY27-QFLUPjoldnkRCXFSCC7rMQNxTitdOOIjsHSY\" rel=\"nofollow\" target=\"_blank\">mfitzhugh@lifescicomms.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyMjc3NSM3MTI4ODUxIzUwMDExMDg1NQ==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/M2Y2MThmYjQtNjI1ZS00ZmEwLWJkMTctN2ExZTczYmFkZGY5LTUwMDExMDg1NS0yMDI1LTA5LTA0LWVu\/tiny\/Cidara-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO, Sept. 04, 2025 (GLOBE NEWSWIRE) &#8212; Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak\u00ae platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that company management will participate in the below September investor conferences. Details are as follows: Event: H.C. Wainwright 27th Annual Global Investment ConferenceDate: September 8, 2025Time: 4:00 PM ETFormat: Corporate Presentation Event: Morgan Stanley 23rd Annual Global Healthcare ConferenceDate: September 9, 2025Time: 7:00 AM ETFormat: Fireside Chat Cidara will also participate in one-on-one investor meetings during the conferences. About Cidara Therapeutics Cidara Therapeutics is using its proprietary Cloudbreak\u00ae\u00a0platform to develop novel drug-Fc conjugates (DFCs) comprising targeted small molecules or peptides coupled to a proprietary human antibody fragment. Cidara\u2019s lead DFC candidate, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-to-participate-in-september-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Cidara Therapeutics to Participate in September Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-881940","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cidara Therapeutics to Participate in September Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-to-participate-in-september-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cidara Therapeutics to Participate in September Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, Sept. 04, 2025 (GLOBE NEWSWIRE) &#8212; Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak\u00ae platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that company management will participate in the below September investor conferences. Details are as follows: Event: H.C. Wainwright 27th Annual Global Investment ConferenceDate: September 8, 2025Time: 4:00 PM ETFormat: Corporate Presentation Event: Morgan Stanley 23rd Annual Global Healthcare ConferenceDate: September 9, 2025Time: 7:00 AM ETFormat: Fireside Chat Cidara will also participate in one-on-one investor meetings during the conferences. About Cidara Therapeutics Cidara Therapeutics is using its proprietary Cloudbreak\u00ae\u00a0platform to develop novel drug-Fc conjugates (DFCs) comprising targeted small molecules or peptides coupled to a proprietary human antibody fragment. Cidara\u2019s lead DFC candidate, &hellip; Continue reading &quot;Cidara Therapeutics to Participate in September Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-to-participate-in-september-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-04T13:16:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyMjc3NSM3MTI4ODUxIzUwMDExMDg1NQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cidara-therapeutics-to-participate-in-september-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cidara-therapeutics-to-participate-in-september-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cidara Therapeutics to Participate in September Investor Conferences\",\"datePublished\":\"2025-09-04T13:16:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cidara-therapeutics-to-participate-in-september-investor-conferences\\\/\"},\"wordCount\":237,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cidara-therapeutics-to-participate-in-september-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUyMjc3NSM3MTI4ODUxIzUwMDExMDg1NQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cidara-therapeutics-to-participate-in-september-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cidara-therapeutics-to-participate-in-september-investor-conferences\\\/\",\"name\":\"Cidara Therapeutics to Participate in September Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cidara-therapeutics-to-participate-in-september-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cidara-therapeutics-to-participate-in-september-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUyMjc3NSM3MTI4ODUxIzUwMDExMDg1NQ==\",\"datePublished\":\"2025-09-04T13:16:52+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cidara-therapeutics-to-participate-in-september-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cidara-therapeutics-to-participate-in-september-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cidara-therapeutics-to-participate-in-september-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUyMjc3NSM3MTI4ODUxIzUwMDExMDg1NQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUyMjc3NSM3MTI4ODUxIzUwMDExMDg1NQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cidara-therapeutics-to-participate-in-september-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cidara Therapeutics to Participate in September Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cidara Therapeutics to Participate in September Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-to-participate-in-september-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Cidara Therapeutics to Participate in September Investor Conferences - Market Newsdesk","og_description":"SAN DIEGO, Sept. 04, 2025 (GLOBE NEWSWIRE) &#8212; Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak\u00ae platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that company management will participate in the below September investor conferences. Details are as follows: Event: H.C. Wainwright 27th Annual Global Investment ConferenceDate: September 8, 2025Time: 4:00 PM ETFormat: Corporate Presentation Event: Morgan Stanley 23rd Annual Global Healthcare ConferenceDate: September 9, 2025Time: 7:00 AM ETFormat: Fireside Chat Cidara will also participate in one-on-one investor meetings during the conferences. About Cidara Therapeutics Cidara Therapeutics is using its proprietary Cloudbreak\u00ae\u00a0platform to develop novel drug-Fc conjugates (DFCs) comprising targeted small molecules or peptides coupled to a proprietary human antibody fragment. Cidara\u2019s lead DFC candidate, &hellip; Continue reading \"Cidara Therapeutics to Participate in September Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-to-participate-in-september-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2025-09-04T13:16:52+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyMjc3NSM3MTI4ODUxIzUwMDExMDg1NQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-to-participate-in-september-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-to-participate-in-september-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cidara Therapeutics to Participate in September Investor Conferences","datePublished":"2025-09-04T13:16:52+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-to-participate-in-september-investor-conferences\/"},"wordCount":237,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-to-participate-in-september-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyMjc3NSM3MTI4ODUxIzUwMDExMDg1NQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-to-participate-in-september-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-to-participate-in-september-investor-conferences\/","name":"Cidara Therapeutics to Participate in September Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-to-participate-in-september-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-to-participate-in-september-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyMjc3NSM3MTI4ODUxIzUwMDExMDg1NQ==","datePublished":"2025-09-04T13:16:52+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-to-participate-in-september-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-to-participate-in-september-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-to-participate-in-september-investor-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyMjc3NSM3MTI4ODUxIzUwMDExMDg1NQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyMjc3NSM3MTI4ODUxIzUwMDExMDg1NQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-to-participate-in-september-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cidara Therapeutics to Participate in September Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/881940","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=881940"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/881940\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=881940"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=881940"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=881940"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}